Results 11 to 20 of about 5,144 (141)

Risk Factors of Ixekizumab-Induced Injection Site Reactions in Patients with Psoriatic Diseases: Report from a Single Medical Center

Biomedicines, 2023
Ixekizumab (Taltz®) is a humanized anti-IL-17A monoclonal antibody approved for the treatment of various inflammatory diseases including psoriasis and psoriatic arthritis.
I-Heng Chiu, Tsen-Fang Tsai
doaj   +1 more source

Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks

Rheumatology and Therapy, 2020
Introduction Patients with ankylosing spondylitis (AS) are burdened with symptoms impacting work productivity measured by presenteeism, absenteeism, overall work impairment, and activity impairment.
Helena Marzo-Ortega, Philip J. Mease, Proton Rahman, Victoria Navarro-Compán, Vibeke Strand, Maxime Dougados, Bernard Combe, James Cheng-Chung Wei, Xenofon Baraliakos, Theresa Hunter, David Sandoval, Xiaoqi Li, Baojin Zhu, Louis Bessette, Atul Deodhar   +14 more
doaj   +1 more source

Efficacy and safety of ixekizumab versus adalimumab in patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomised SPIRIT-H2H trial

Dermatology Practical & Conceptual, 2022
Introduction: The randomised, open-label, assessor-blinded, parallel-group SPIRIT-H2H trial (NCT03151551) demonstrated superiority of ixekizumab over adalimumab in simultaneously achieving improvement in joint symptoms (American College of Rheumatology [
Kristian Reich, Lars Erik Kristensen, Saxon D. Smith, Phoebe Rich, Christophe Sapin, Soyi Liu Leage, Robert McKenzie, Christopher Schuster, Elisabeth Riedl, Melinda Gooderham   +9 more
doaj   +1 more source

Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection

Journal of Inflammation Research, 2021
John Miller,1,2 Abin P Puravath,1 Ana-Maria Orbai1,3 1Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; 2Lyme Disease Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; 3Psoriatic ...
Miller J, Puravath AP, Orbai AM
doaj  

T cell epitope mapping of secukinumab and ixekizumab in healthy donors

mAbs, 2020
Secukinumab, a human monoclonal antibody that selectively neutralizes IL-17A, has consistently shown low anti-drug antibody responses in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Sebastian Spindeldreher, Anette Karle, Evelyne Correia, Maxime Tenon, Sascha Gottlieb, Thomas Huber, Bernard Maillere, Frank Kolbinger   +7 more
doaj   +1 more source

Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension

Acta Dermato-Venereologica, 2017
Itching is a prevalent plaque psoriasis symptom. Ixekizumab, an IL-17A antagonist, has demonstrated rapid, significant improvements in itch severity over 12 weeks in Phase III psoriasis trials (UNCOVER-1, UNCOVER-2). We assessed the long-term (through 60
Alexandra B. Kimball, Thomas Luger, Alice Gottlieb, Luis Puig, Roland Kaufmann, Russel Burge, Chen-Yen Lin, Gil Yosipovitch   +7 more
doaj   +1 more source

An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis

Acta Dermato-Venereologica, 2020
Patient-reported outcomes are valuable for assessing new psoriasis therapies. This study investigated patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with ixekizumab or ustekinumab, dosed according to their ...
Lluís Puig, Mark Lomaga, Kristin Hollister, Yves Dutronc, Lovisa Berggren, Peter C.M. van de Kerkhof   +5 more
doaj   +1 more source

Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy

Global & Regional Health Technology Assessment, 2021
Background: Interleukin (IL) inhibitors achieve greater levels of efficacy than older systemic therapies. We calculated the number needed to treat (NNT) of ixekizumab compared with other IL inhibitors approved in Italy for the treatment of moderate-to ...
Roberto Ravasio, Antonio Costanzo, Silvia Antonelli, Alessia Maiorino, Serena Losi   +4 more
doaj   +1 more source

Ixekizumab Survival in Heavily Pretreated Patients with Psoriasis: A Two-year Single-centre Retrospective Study

Acta Dermato-Venereologica, 2020
The long-term effect of intra-anti-interleukin-17-class switch on drug survival is unclear. The aim of this study was to evaluate the efficacy and long-term survival of ixekizumab in bio-experienced psoriatic patients with and without previous exposure ...
Shany Sherman, Ory Zloczower, Yehonatan Noyman, Iris Amitay-Laish, Emmilia Hodak, Lev Pavlovsky   +5 more
doaj   +1 more source

Severe drug-associated colitis with Crohn’s features in setting of ixekizumab therapy for chronic plaque psoriasis

BMC Gastroenterology, 2021
Background Ixekizumab is monoclonal antibody targeted against interleukin-17 (IL-17) and has been approved for use in chronic plaque psoriasis. Despite its efficacy in treating psoriasis, concerns have been raised regarding Ixekizumab’s potential to ...
Xin Mu, John Fardy, Stephanie Reid, Julia Trahey   +3 more
doaj   +1 more source